The Catalonian high-volume HDF study data are clearly impressive — confirming our original conviction that every patient should get the chance to benefit from HighVolumeHDF®.
|risk reduction in all-cause mortality (p=0.01)|
|risk reduction in mortality from infection (p=0.03)|
|risk reduction in mortality from stroke (p=0.03)|
Compared with patients maintained on conventional high-flux haemodialysis, those randomised to high-efficiency postdilution online haemodiafiltration had a significantly lower all-cause mortality. The estimated number needed to treat (NNT) showed that to prevent one annual death eight patients would need to be switched from haemodialysis to online haemodiafiltration.
|risk reduction in incidence of hypotensive episodes (p<0.001)|
|risk reduction in all-cause hospitalisation (p=0.001)|
To compare the impact of online haemodiafiltration over haemodialysis on patient survival.
Multi-centre, prospective randomised controlled trial promoted by the Catalonian Society of Nephrology
The primary outcome variable was all-cause mortality, and secondary outcomes included cardiovascular mortality, all-cause hospitalisation, treatment tolerance and laboratory data.
906 chronic haemodialysis patients were assigned either to continue haemodialysis (n=450) or to be switched to high-efficiency postdilution online haemodiafiltration (n=456).
1 Maduell F. et al., J Am Soc Nephrol (2013); 24: 487-497.
Results of the Catalonian high-volume HDF study, recently published in the Journal of the American Society of Nephrology, were presented at Fresenius Medical Care’s Scientific Lunch Symposium at ERA-EDTA Congress 2013, held in Istanbul, Turkey by the lead study investigator, Dr. Francisco Maduell of Barcelona, Spain.
The overwhelming number of more than 1,000 participants at the symposium demonstrated the significant interest in the topic “Emerging Concept: High Volume Matters in Haemodiafiltration (high-volume HDF)”.